6月4日，据CDE官网消息，深圳信立泰药业股份有限公司联合申请药品“SAL0112片”，获得临床试验默示许可，受理号CXHB2500063。
公示信息显示，药品“SAL0112片”适应症：本品适用于成人肥胖患者或伴发一种及以上与体重相关危险因素（如高血压、2 型糖尿病或血脂异常等）的超重患者的体重管理、成人2型糖尿病患者的血糖控制。
深圳信立泰药业股份有限公司，成立于1998年，位于深圳市，是一家以从事医药制造业为主的企业。企业注册资本111481.6535万人民币，实缴资本66311.3804万人民币。
通过天眼查大数据分析，深圳信立泰药业股份有限公司共对外投资了17家企业，参与招投标项目5000次，知识产权方面有商标信息286条，专利信息276条，此外企业还拥有行政许可220个。
主要股东信息显示，深圳信立泰药业股份有限公司由无限售流通股持股99.9797%、限售流通股（或非流通股）持股0.0203%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.